Annual report
9776.TEDINET S100TWXM
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥19.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥535m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥1.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥515m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥983m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥598m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥960m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥380m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥794m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥528m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥363m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥641m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥16.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥16.1bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥14.5bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥11.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.5bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.2bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.3bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥9.3bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥8.5bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥838m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥395m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥409m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥831m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥370m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥348m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥113m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥52m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥114.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.16 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥231.85 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.3 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,283.71 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,178.25 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,016.24 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,708.63 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,472.23 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 65.6% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 3.5% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.8% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 871 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 938 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 871 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 819 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 820 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥17.3bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥17.6bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥17.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥16.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥16.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥369m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥705m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥598m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥895m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥944m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥681m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥696m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥460m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥472m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥1.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥791m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥503m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥15.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥14.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥14.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥13.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥10.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.4bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥4.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥10.6bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.2bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥9.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥9.0bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥8.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥3.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥138.25 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥141.47 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥300.67 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥231.1 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.04 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥23 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥23 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥23 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥23 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,194.85 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,066.27 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,934.15 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,633.22 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,398.25 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 70.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.4% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,216,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 635 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 627 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 622 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 775 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 779 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 87
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 3 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥131m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥126m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥48m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥90m |
| Clinical Testing Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥124m |
| Clinical Testing Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥284m |
| Clinical Testing Businessreportable segment | employees | at 2024-03-31 | 539 pure |
| Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥7.6bn |
| Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥7.6bn |
| Clinical Testing Businessreportable segment | segment assets | at 2024-03-31 | ¥3.5bn |
| Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥109m |
| Dispensing Pharmacy Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥193m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥109m |
| Dispensing Pharmacy Businessreportable segment | employees | at 2024-03-31 | 287 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2024-03-31 | ¥3.4bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥733m |
| Medical Devices Sales And Maintenance Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥25m |
| Medical Devices Sales And Maintenance Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥8m |
| Medical Devices Sales And Maintenance Businessreportable segment | employees | at 2024-03-31 | 21 pure |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥937m |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥626m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment assets | at 2024-03-31 | ¥723m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥9m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥342m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥401m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥20.2bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥19.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥626m |
| —segment total | segment assets | at 2024-03-31 | ¥7.6bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥834m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥346m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥403m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥20.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥19.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥632m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥7.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥924m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥354,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥116m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥113m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥44m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥75m |
| Clinical Testing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥379m |
| Clinical Testing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥250m |
| Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥8.3bn |
| Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥8.3bn |
| Clinical Testing Businessreportable segment | segment assets | at 2023-03-31 | ¥4.0bn |
| Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥564m |
| Dispensing Pharmacy Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥139m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥120m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥10.7bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥10.7bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2023-03-31 | ¥3.3bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥821m |
| Medical Devices Sales And Maintenance Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥7m |
| Medical Devices Sales And Maintenance Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥8m |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.7bn |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.0bn |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥676m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment assets | at 2023-03-31 | ¥745m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥5m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥525m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥378m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥20.7bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥20.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥676m |
| —segment total | segment assets | at 2023-03-31 | ¥8.0bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥525m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥20.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥20.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥679m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 3 pure |
| Clinical Testing Businessreportable segment | employees | at 2024-03-31 | 324 pure |
| Dispensing Pharmacy Businessreportable segment | employees | at 2024-03-31 | 287 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,541
| Item | Context | Value | Unit |
|---|---|---|---|
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)北海道財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-06-27 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第60期（自 2023年４月１日 至 2024年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)札幌臨床検査センター株式会社 | |
| Company name in english cover page | FilingDateInstant | SAPPORO CLINICAL LABORATORY INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 伊達 忠應 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北三条西十八丁目２番地２ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | ０１１（６１３）３２１０ | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)総務部長 南 誠 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北三条西十八丁目２番地２ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０１１（６１３）３２１０ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)総務部長 南 誠 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E04950 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 97760 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)札幌臨床検査センター株式会社 | |
| Filer name in english | FilingDateInstant | SAPPORO CLINICAL LABORATORY INC. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2024-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)(株)札幌ミライラボラトリー | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |